Hemihepatectomy: Outcomes With Laparoscopic vs Open Surgery

In a phase III study, investigators found that among patients with indications for hemihepatectomy suitable for both laparoscopic and open approaches, of whom the majority had cancer, the laparoscopic approach was associated with a shorter time to functional recovery vs open surgery.

For Detection of Measurable Residual Disease in Ovarian Cancer, Are Two Methods Better Than One?

In patients with ovarian cancer, second-look surgery may find a role again. The evaluation of measurable residual disease (MRD) using second-look laparoscopy identified more women who had detectable MRD after front-line treatment than did circulating tumor DNA, according to a study presented at the Society of Gynecologic Oncology 2024 Annual Meeting on Women’s Cancer.

T-DXd vs Physician’s Choice of Therapy in HER2-Positive Metastatic Breast Cancer: PROs in DESTINY-Breast02

An analysis of patient-reported outcomes (PROs) in the DESTINY-Breast02 trial found that general health status/quality of life was maintained over time with fam-trastuzumab deruxtecan-nxki (T-DXd) vs physician’s choice of therapy in patients with HER2-positive unresectable or metastatic breast cancer previously treated with ado-trastuzumab emtansine. Time to deterioration in PROs was also longer with T-DXd.